Back

Evolution of immune escape mechanisms in the progression from preinvasive to invasive human lung adenocarcinoma.

Altorki, N. K.; Borczuk, A. C.; Mittal, V.; Elemento, O.; McGraw, T. E.

2020-04-18 cancer biology
10.1101/2020.04.17.046540 bioRxiv
Show abstract

The tumor microenvironment (TME) of lung adenocarcinoma (LUAD) precursor lesions has not been described. We interrogated by multiplex immunofluorescence the TME of preinvasive and invasive Stage 1A LUADs selected by computer tomography (CT) scan-density. Pure non-solid (p-NS) CT density nodules are preinvasive/minimally invasive, whereas solid CT density nodules are frankly invasive cancers. Our data reveal an intensely immune-suppressive immune TME in p-NS tumors characterized by an increase in Treg cells and a decrease in cytotoxic T cells relative to normal lung. The TME of the solid tumor group, more advanced lesions than the p-NS yet still early in disease development, were increasingly more immune-suppressive. Provocatively, there was a further increase in both Treg cells and cytotoxic T cells, establishing a nascent albeit ineffective anti-tumor immune response in transition from preinvasive p-NS to invasive solid tumors. Regulatory T cells play a dominant role throughout progression, while additional immune evasive mechanisms are employed at different stages of disease progression, including T cell exclusion from cancer cell nests early and activation of immune checkpoints later. Our study establishes that different immune-targeted strategies are required to intercept disease progression at these two distinct early points of lung cancer development. Statement of SignificanceUsing multiplexed IF, we compared the cellular composition and activation state of the tumor immune microenvironment between pre/minimally invasive and frankly invasive adenocarcinoma. We found a progressive increase in immunosuppressive mechanisms in association with disease progression suggesting that Interception strategies should be specifically tailored based on underlying immune escape mechanisms

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
EBioMedicine
39 papers in training set
Top 0.1%
14.2%
2
Frontiers in Immunology
586 papers in training set
Top 0.8%
8.3%
3
Nature Communications
4913 papers in training set
Top 29%
6.3%
4
Molecular Oncology
50 papers in training set
Top 0.1%
4.3%
5
Cancers
200 papers in training set
Top 1%
4.3%
6
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.3%
3.9%
7
JCI Insight
241 papers in training set
Top 1%
3.5%
8
eLife
5422 papers in training set
Top 26%
3.5%
9
OncoImmunology
22 papers in training set
Top 0.1%
3.0%
50% of probability mass above
10
PLOS ONE
4510 papers in training set
Top 43%
3.0%
11
Scientific Reports
3102 papers in training set
Top 46%
2.6%
12
Cancer Research
116 papers in training set
Top 2%
2.1%
13
Immunology
29 papers in training set
Top 0.5%
1.7%
14
Oncogene
76 papers in training set
Top 1%
1.7%
15
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.1%
1.6%
16
Cell Reports
1338 papers in training set
Top 26%
1.5%
17
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
1.3%
18
The Journal of Pathology
22 papers in training set
Top 0.2%
1.3%
19
Molecular Cancer Research
42 papers in training set
Top 0.4%
1.3%
20
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.2%
21
Frontiers in Oncology
95 papers in training set
Top 3%
1.2%
22
Genome Medicine
154 papers in training set
Top 6%
1.2%
23
Clinical Cancer Research
58 papers in training set
Top 1%
0.9%
24
eBioMedicine
130 papers in training set
Top 3%
0.9%
25
Acta Neuropathologica Communications
81 papers in training set
Top 1.0%
0.9%
26
Cancer Discovery
61 papers in training set
Top 2%
0.8%
27
Translational Oncology
18 papers in training set
Top 0.4%
0.8%
28
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.7%
0.7%
29
Molecular Cancer
14 papers in training set
Top 1%
0.7%
30
PLOS Pathogens
721 papers in training set
Top 9%
0.7%